Lexicon Pharmaceuticals, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Lexicon Pharmaceuticals, Inc. now
Current reporting with the operating signal separated from the noise.
Lexicon Pharmaceuticals, Inc.: Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
The story matters when it changes Lexicon Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Lexicon Pharmaceuticals, Inc. (LXRX) Q1 FY2026 earnings call transcript
Investors are testing whether Lexicon Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call Transcript
Investors are testing whether Lexicon Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Lexicon Pharmaceuticals, Inc. Q3 2025 Earnings Call Summary
Investors are testing whether Lexicon Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript
Investors are testing whether Lexicon Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest LXRX filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Lexicon Pharmaceuticals, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.